RenovaCare, Inc. (RCAR)

[jason_luke]

Renovacare has not started a clinical trial. It will be many, many years before their product could even have a chance at generating revenue. Meanwhile, Avita Medical (AVMXY) just met both primary endpoints in a Phase 3 pivotal trial and is set to commercialize Recell in early 2018 for burn care. Avita also has a $60,000,000 U.S. federal government with BARDA, and under the terms of that contract, BARDA has agreed to purchase 5,000 Recell units for $8,000,000 which could drop anytime really. Avita market cap = under 50 million. Renovacare market cap = 300 million. Renovacare U.S. share count = 75M (and doing a raise as we speak); Avita U.S. share count = 33.5M. And finally, no Typhoon, Renovacare doesn't hold the PATENTS lol. Sorry brother, Avita has much stronger patents in this space and the patent board IMO will agree as such. Renovacare in my humble opinion has peaked and is on the way down.